-
Oct 16, 2024 Voluntary Recall of twenty-seven ( 27 ) lots of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP)
-
Aug 7, 2024 Apotex expands ophthalmic franchise through the acquisition of Canadian rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%), a novel steroid for ophthalmology
-
Jul 3, 2024 Apotex Further Expands Oncology Franchise Through the Acquisition of Canadian Rights to Toripalimab
-
Jun 3, 2024 Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company
-
Apr 2, 2024 Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader
-
Feb 16, 2024 Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
-
Aug 9, 2023 Voluntary Recall of seven ( 7 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard)
-
Aug 9, 2023 Voluntary Recall of three ( 3 ) lots of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP)
-
Apr 3, 2023 SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals
-
Feb 1, 2023 Voluntary Recall of one ( 1 ) lot of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg - Lot PY1904
-
Dec 16, 2022 Accessa becomes the patient support program manager for Apotex Inc.'s Apo-Deferasirox™ and Apo-Deferasirox (Type J)™ products.
-
Sep 28, 2022 SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals
-
Jul 27, 2022 Voluntary Recall of four ( 4 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg
-
Jul 20, 2022 First Generic Alternative to Eliquis® Now Available in Canada
-
May 17, 2022 Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis
-
Apr 26, 2022 Voluntary Recall of five ( 5 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg.
-
Jan 19, 2022 Voluntary Recall of one ( 1 ) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot PY1832.
-
Nov 30, 2021 Canada-Wide Contest Recognizes the Impact of Pharmacy Professionals on Patient Care
-
Nov 9, 2021 Patient Access to Affordable Cancer Treatment Increases with the Launch of New Biosimilar in Canada
-
Sep 30, 2021 VOLUNTARY NATIONWIDE RECALL: ONE LOT OF Mirvala™ 28 (Desogestrel and Ethinyl Estradiol Tablets, USP) 0.150 mg / 0.030 mg DUE TO POSSIBILITY OF ONE PLACEBO PILL IN PLACE OF AN ACTIVE PILL
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Nov 17, 2026
Apotex launches APO-LINAGLIPTIN™, expanding access to treatment options for Canadians living with type 2 diabetes
TORONTO, ON, November 16, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), the largest Canadian-based global health company, today announced the launch of APO-LINAGLIPTIN™ (linagliptin tablets), the latest addition to its portfolio of medicines.
-
Nov 12, 2026
Apotex Announces Second Quarter 2027 Results
TORONTO, ON, November 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada’s largest pharmaceutical company, today announced its financial and operating results for the three and six months ended September 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.
-
Oct 9, 2026
Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.